Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Wendys Co — how do they compare? Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B), while Wendys Co trades at $7.54 (market cap $1.39B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 95.5× Wendys Co's market cap, and Wendys Co pays a 3.84% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | WEN | |
|---|---|---|
Market Cap | $132.79B | $1.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $529.65 | $10.68 |
52-Week Low | $376.62 | $6.17 |
Enterprise Value | $126.92B | $5.12B |
Dividend Yield | — | 3.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Wendy's stock (WEN) trades at $7.69, up 4.06% in the last session, with a bullish technical signal from moving averages and a consensus price target of $9.33. Recent Q2 2026 EPS beat estimates at $0.18, but revenue trends show stagnation near $2.2B, with net income declining to $165M in 2025. The company faces headwinds from a dividend cut and lost market share to Burger King, as new leadership pursues a turnaround plan amid weak U.S. traffic.
The outlook is cautious; valuation ratios like P/E of 11.67 and P/S of 0.67 suggest undervaluation, but high debt and competitive pressures pose risks. Analyst sentiment is mixed with 62.75% hold ratings, reflecting uncertainty over the turnaround's success. Near-term performance hinges on execution of strategic initiatives to revive sales and margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
